Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Fudan University
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Age range 18-70 years old

• Histological confirmed diffuse large B cell lymphoma

• ECOG performance status no more than 2

• Life expectancy of more than 3 months

• Relapse or refractory after the first-line chemotherapy of DLBCL

• No evidence of bone marrow involvement

• Normal laboratory values: hemoglobin > 8.0g/dl, neutrophil > 1.5×109/L, platelet > 80×109/L, serum creatine < 1× upper limitation of normal(ULN), serum bilirubin < 1× ULN, ALT and AST < 1.5× ULN

Exclusion Criteria:

• Pregnant or lactating women

• Serious uncontrolled diseases and intercurrent infection

• The evidence of CNS metastasis and bone marrow involvement

• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

• History of allergic reaction/hypersensitivity to rituximab